Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Flotation

Lemonade demonstrates $319m flotation
2nd July 2020
Robert Lavine
SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property isnurance provider Lemonade priced the initial public offering above its range.
Shift gears up for reverse merger
1st July 2020
Thierry Heles
The Lithia Motors, BMW and Alliance Ventures-backed automotive e-commerce marketplace is set to go public through a reverse merger with Insurance Acquisition.
Pandion plans $75m initial public offering
30th June 2020
Robert Lavine
SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.
Akouos acquires $213m in initial public offering
29th June 2020
Robert Lavine
The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.
Fusion Pharma fetches $213m in IPO
29th June 2020
Robert Lavine
Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.
Agora accomplishes $350m flotation
26th June 2020
Robert Lavine
The SIG-backed video communication software provider priced its shares above the range and will go public later today.
Forma Therapeutics finishes IPO at $319m
24th June 2020
Robert Lavine
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Repare rounds off $253m initial public offering
24th June 2020
Robert Lavine
Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

Other News

Genetron jumps to public markets in $256m IPO
23rd June 2020
Robert Lavine
Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.
Forma forces its way to $278m IPO
19th June 2020
Robert Lavine
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Repare reaches public markets with $220m
19th June 2020
Robert Lavine
The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.
Kangua canters to $149m IPO
19th June 2020
Robert Lavine
Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.
Burning Rock blazes a trail on to public markets
16th June 2020
Robert Lavine
The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.
Vaxcyte racks up $250m in IPO
16th June 2020
Robert Lavine
Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Editor's Picks

Lemonade demonstrates $319m flotation
2nd July 2020
Robert Lavine
SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property isnurance provider Lemonade priced the initial public offering above its range.
Forma Therapeutics finishes IPO at $319m
24th June 2020
Robert Lavine
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Forma forces its way to $278m IPO
19th June 2020
Robert Lavine
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Avidity achieves $259m initial public offering
15th June 2020
Robert Lavine
Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.
© 2020 Mawsonia Ltd. All rights reserved.
test reg

Login

Forgot password?

Not yet subscribed?

See your subscription offers here